OA10204A - Squalene synthetase inhibitors - Google Patents

Squalene synthetase inhibitors Download PDF

Info

Publication number
OA10204A
OA10204A OA60759A OA60759A OA10204A OA 10204 A OA10204 A OA 10204A OA 60759 A OA60759 A OA 60759A OA 60759 A OA60759 A OA 60759A OA 10204 A OA10204 A OA 10204A
Authority
OA
OAPI
Prior art keywords
neopentyl
compound
oxo
chloro
trans
Prior art date
Application number
OA60759A
Other languages
English (en)
Inventor
Ernest S Hamanaka
Joel M Hawkins
Cheryl M Hayward
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA10204A publication Critical patent/OA10204A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
OA60759A 1994-12-23 1995-12-22 Squalene synthetase inhibitors OA10204A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36271394A 1994-12-23 1994-12-23

Publications (1)

Publication Number Publication Date
OA10204A true OA10204A (en) 1996-12-18

Family

ID=23427229

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60759A OA10204A (en) 1994-12-23 1995-12-22 Squalene synthetase inhibitors

Country Status (26)

Country Link
US (1) US5770594A (fr)
JP (1) JPH10500702A (fr)
KR (1) KR960022510A (fr)
CN (1) CN1133287A (fr)
AU (1) AU4067795A (fr)
BG (1) BG100248A (fr)
BR (1) BR9505995A (fr)
CA (1) CA2207772A1 (fr)
CZ (1) CZ344795A3 (fr)
FI (1) FI972696L (fr)
GT (1) GT199500058A (fr)
HU (1) HUT74672A (fr)
IL (1) IL116399A0 (fr)
IS (1) IS4312A (fr)
LV (1) LV11325B (fr)
MA (1) MA23746A1 (fr)
MX (1) MX9704683A (fr)
NO (1) NO955288L (fr)
OA (1) OA10204A (fr)
PE (1) PE60096A1 (fr)
PL (1) PL311997A1 (fr)
SI (1) SI9500393A (fr)
SK (1) SK158795A3 (fr)
TN (1) TNSN95133A1 (fr)
TR (1) TR199501644A2 (fr)
WO (1) WO1996020184A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048701A1 (fr) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines ou 4,1-benzothiazepines et leur utilisation comme inhibiteurs de squalene synthetase
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6403576B1 (en) * 1998-08-24 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Antifungal and antiparasitic compounds
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
CA2389973A1 (fr) * 1999-11-04 2001-05-10 Andrx Corporation Methode de traitement de troubles lies au precurseur beta-amyloide
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
ES2328225T3 (es) * 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
WO2008121602A1 (fr) * 2007-03-29 2008-10-09 Smithkline Beecham Corporation Composés chimiques
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG82630A1 (en) * 1992-04-20 2001-08-21 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5807834A (en) * 1994-09-20 1998-09-15 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor

Also Published As

Publication number Publication date
HUT74672A (en) 1997-01-28
MA23746A1 (fr) 1996-07-01
WO1996020184A1 (fr) 1996-07-04
KR960022510A (ko) 1996-07-18
US5770594A (en) 1998-06-23
IS4312A (is) 1996-06-24
AU4067795A (en) 1996-07-04
CN1133287A (zh) 1996-10-16
TNSN95133A1 (fr) 1996-02-06
IL116399A0 (en) 1996-03-31
MX9704683A (es) 1997-09-30
CA2207772A1 (fr) 1996-07-04
JPH10500702A (ja) 1998-01-20
LV11325A (lv) 1996-06-20
NO955288L (no) 1996-06-24
CZ344795A3 (en) 1996-09-11
HU9503783D0 (en) 1996-04-29
LV11325B (en) 1997-02-20
FI972696A0 (fi) 1997-06-23
GT199500058A (es) 1997-06-05
SK158795A3 (en) 1997-01-08
FI972696A7 (fi) 1997-06-23
NO955288D0 (no) 1995-12-22
TR199501644A2 (tr) 1996-11-21
SI9500393A (en) 1997-04-30
FI972696L (fi) 1997-06-23
PL311997A1 (en) 1996-06-24
PE60096A1 (es) 1996-12-28
BG100248A (bg) 1996-07-31
BR9505995A (pt) 1997-12-23

Similar Documents

Publication Publication Date Title
JP5203361B2 (ja) プロリルヒドロキシラーゼ阻害剤
US8101615B2 (en) 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
CN1210268C (zh) ((环)烷基取代的)-γ-氨基丁酸衍生物(=GABA类似物),其制备和在治疗神经病中的用途
US6677333B1 (en) 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
EP1438310B1 (fr) Derives de beta-carboline en tant qu'inhibiteurs de ptp
BRPI0806566A2 (pt) Derivados de glicina n-substituída: inibidores de hidroxilase
US10085986B2 (en) Pyrimidinone compounds and their use
CA2208174A1 (fr) Inhibiteurs du squalene synthetase
NZ550114A (en) Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
US20110098324A1 (en) Prolyl hydroxylase inhibitors
CN1040755C (zh) 杂环化合物的制备方法
US20100022541A1 (en) Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
US5770594A (en) Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase inhibitors
SK8972002A3 (en) Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP4402176B2 (ja) 新規アミド化合物及びこれを含有する医薬
KR19990014070A (ko) 파네실 전이효소 저해활성을 갖는 히단토인 유도체
EP3423467B1 (fr) Nouveaux dérivés de diflurokétamide comme inhibiteurs de la htra1
AU2011224417B2 (en) 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
JP4647726B2 (ja) 新規なアニリド化合物及びこれを含有する医薬
US6605604B1 (en) Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them
EP3504197B1 (fr) Nouveaux dérivés de trifluorométhylpropanamide utilisés comme inhibiteurs de htra1
WO2012158399A1 (fr) 2-carbamoylpyridazinones condensées en tant que modulateurs des canaux potassiques
HK40077414A (en) Pyrimidine formamide compound and use thereof
JPH06239859A (ja) アンギオテンシンii拮抗作用を有する環状化合物およびその用途
HK1130671B (en) Prolyl hydroxylase inhibitors